Tech Company Financing Transactions
FogPharma Funding Round
venBio, 6 Dimensions Capital and Blue Pool Capital invested in a $107 million Series C funding round for FogPharma. The financing round was announced on 3/2/2021.
Transaction Overview
Company Name
Announced On
3/2/2021
Transaction Type
Venture Equity
Amount
$107,000,000
Round
Series C
Investors
Proceeds Purpose
Proceeds from the Series C financing will allow FogPharma to advance its lead, only-in-class Helicon peptides aimed at addressing substantial cancer patient populations into clinical development.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
30 Acorn Park Dr.
Cambridge, MA 02140
USA
Cambridge, MA 02140
USA
Phone
Website
Email Address
Overview
FogPharma was born from the scientific and entrepreneurial vision of founder Greg Verdine, a pioneer in the discovery and development of new drug classes that 'drug the undruggable.' FogPharma's cell-penetrating miniproteins (CPMPs) are a broad new class of medicines that can drug targets beyond the reach of conventional therapeutics.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gregory Verdine
Chief Financial Officer
Tony Gibney
Chief Operating Officer
WeiQing Zhou
Chief Scientific Officer
Howard Stern
Vice President
Jonathan Hurov
Vice President
Martin Tremblay
VP - Finance
Stephen Fair
VP - Human Resources
Sandra Smith
Browse more venture capital transactions:
Prev: 3/2/2021: Carisma Therapeutics venture capital transaction
Next: 3/3/2021: Nuvolo venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on all VC transactions involving tech companies. VC investment data records reported here are sourced from publicly available VC deal announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs